P38 ALPHA INHIBITION
A REASON TO BELIEVE THAT MEMORY DEFICITS DUE TO ALZHEIMER’S DISEASE CAN BE REVERSED
For the 5.2 million Americans suffering from Alzheimer’s Disease (AD), identity and memory are fleeting wisps of clarity in an ever-thickening fog of confusion. Until recently, experimental therapies developed for AD focused on preventing build-up of amyloid plaques to slow disease progression with little success. EIP Pharma is charting a new course - focused on reversing the synaptic dysfunction that, regardless of the cause, underlies the memory deficits in Alzheimer’s disease.
p38 alpha is expressed in neurons in times of stress and disease, and irregular p38 alpha activity within the neuron can contribute to synaptic dysfunction. Synaptic dysfunction has emerged as the major driver in the development of memory deficits in Alzheimer’s disease.
Today, neflamapimod is our sole focus – a selective, small molecule oral inhibitor of p38 alpha. Findings in the phase 2a clinical studies strongly suggest that inhibition of p38 alpha with neflamapimod reverses synaptic dysfunction and resulting episodic memory deficits in patients in the early stages of symptomatic Alzheimer's disease.
EIP Pharma Announces Clinical Study Presentations at the 11th Clinical Trials on Alzheimer's Disease Conference and Provides Update on Phase 2b Clinical Study Enrollment